.Attribute Medication, Published online: 30 July 2024 doi:10.1038/ d41591-024-00054-wThe antitoxin-- medicine conjugate (ADC) tisotumab vedotin led to enhanced progression-free and also overall survival, bring about FDA approval and a new treatment choice for individuals.